DUBLIN, April 11, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Research Report on China's Blood Product Industry, 2011-2016" report to their offering.
In 2015, 8,000 tons of blood plasma was needed to meet the demand of Chinese market, and the actual supply was only 5,000 tons.
Blood products made by segregating and purifying all kinds of proteins in the blood plasma consists of albumin, immunoglobulin, thrombinogen and other products. China's enterprises mainly produce 9 kinds of products in the first three categories.
The high concentration rate of the global blood product market is embodied in the three companies of developed countries accounting for more than 80% of the global market. The current global blood market remains relatively stable, of which the emerging economy is the main motivation of growth.
By the end of 2015, there were 33 blood product manufacturing enterprises certified by the government in China, but in fact, only 20 of them were in production. Since 2012, mergers and acquisitions are common in China's blood product industry.
In 2015, 8,000 tons of blood plasma was needed to meet the demand of Chinese market, and the actual supply was only 5,000 tons. For example, the demand for blood products of about 1.4 billion population of China should be 12,000 tons calculated according to per capita demand of the normal blood products of the World Health Organization, which is far more than the actual supply of China.
In China's blood product industry, the scale of the blood plasma has been the main bottleneck restricting the development of blood product industry. The quality and quantity of plasma stations are of vital importance.
Key Topics Covered:
1 Introduction of Blood Products
1.4 Industrial Policies on Blood Product
1.5 Overview on China Blood Product Industry
2 Overview of Global Blood Product Industry, 2011-2015
2.1 Industry Overview
2.2 Major Blood Product Manufacturers in the Globe (Except China)
3 Supply and Demand Status of China Blood Product Industry, 2011-2015 3.1 Development Process 3.2 Barriers to Entry 3.3 Supply 3.4 Demand Status
4 Major Enterprises of China Blood Product Industry, 2011- 2015
4.1 Shanghai RAAS Blood Products Co. Ltd.
4.2 Hualan Biological Engineering Co., Ltd.
4.3 Beijing Tiantan Biological Products Co., Ltd. (Subsidiary of China National Biotec Group Company Limited)
4.4 Guangdong Shuanglin Bio-pharmaceutical Co., Ltd.
4.5 Jiangxi Boya Bio-pharmaceutical Co., Ltd.
4.6 Hunan Nanyue Pharmaceutical Co., Ltd.
4.7 Wuhan Rui De Biological Products Co., Ltd.
4.8 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.9 Green Cross Biological Products Co., Ltd.
4.10 Guiyang Qianfeng Biological Products Co., Ltd.
4.11 Anhui Da'an Biological Products Co., Ltd.
4.12 Shenzhen Weiguang Biological Products Co., Ltd.
4.13 Shandong Taibang Products Co., Ltd.
4.14 Subordinate Institutions of Biological Products of China National Biotec Group
5 Forecast on Development of China Blood Product Industry, 2016-2020 5.1 Supply Forecast 5.2 Demand Forecast 5.3 Forecast on Market Competition
For more information visit http://www.researchandmarkets.com/research/chbz2j/research_report
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets